secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001104659-25-073967
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma
--------------------------------------------------------------------------------

- Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.
- Cash and equivalents $26.8M at June 30; after July ATM from healthcare investor, proforma ~$39M; expected to fund into 2H 2027.
- NXP900 becomes lead candidate; Phase 1a dose escalation and DDI study completed; Phase 1b program initiation imminent.
- NXP800 exploring opportunities in endometrial and prostate cancer; updates expected in coming months.
- R&D expenses $3.6M (incl. $1.8M stock-based comp); G&A $3.0M (incl. $1.8M stock-based comp) for Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/0001104659-25-073967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/tm2522415d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-073967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer